

Paolo Baldo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4840517/paolo-baldo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

421
citations

12
h-index

20
g-index

28
ext. papers

528
ext. citations

3.1
avg, IF

3.68
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 24 | SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces. <i>European Journal of Hospital Pharmacy</i> , 2021 , | 1.6 | 1 |
| 23 | Pharmacovigilance of anti-cancer medicines: opportunities and challenges. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 849-860 | 4.1 | 2 |
| 22 | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019 , 14, 242-257 | 2.6 | 2 |
| 21 | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019 , 14, 226-241 | 2.6 | |
| 20 | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019 , 14, 203-225 | 2.6 | 0 |
| 19 | Pharmacovigilance in oncology. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 832-841 | 2.3 | 22 |
| 18 | Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 748-753 | 2.3 | 2 |
| 17 | EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 778-782 | 2.3 | 5 |
| 16 | An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. <i>Advances in Therapy</i> , 2018 , 35, 1497-1509 | 4.1 | 36 |
| 15 | Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 795-802 | 2.3 | 16 |
| 14 | An historical overview over Pharmacovigilance. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 744-747 | 2.3 | 28 |
| 13 | Amatuximab and novel agents targeting mesothelin for solid tumors. <i>OncoTargets and Therapy</i> , 2017 , 10, 5337-5353 | 4.4 | 24 |
| 12 | Patient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives. <i>Journal of Cancer Education</i> , 2016 , 31, 405-12 | 1.8 | 8 |
| 11 | Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations. <i>Oncology and Therapy</i> , 2016 , 4, 173-182 | 2.7 | 3 |
| 10 | Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2824-5 | 2.2 | 6 |
| 9 | Pharmacovigilance in oncology: evaluation of current practice and future perspectives. <i>Journal of Evaluation in Clinical Practice</i> , 2014 , 20, 559-69 | 2.5 | 17 |
| 8 | Safety and efficacy evaluation of albumin-bound paclitaxel. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 511-20 | 2.0 | 25 |

| | | | |
|---|---|-----|----|
| 7 | Antidepressants for patients with tinnitus. <i>The Cochrane Library</i> , 2012 , CD003853 | 5.2 | 49 |
| 6 | Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. <i>Current Cancer Drug Targets</i> , 2011 , 11, 85-102 | 2.8 | 24 |
| 5 | Interferon-alpha for maintenance of follicular lymphoma. <i>The Cochrane Library</i> , 2010 , CD004629 | 5.2 | 12 |
| 4 | Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin. <i>Tumori</i> , 2009 , 95, 687-690 | 1.7 | 2 |
| 3 | mTOR pathway and mTOR inhibitors as agents for cancer therapy. <i>Current Cancer Drug Targets</i> , 2008 , 8, 647-65 | 2.8 | 86 |
| 2 | A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation. <i>Journal of Evaluation in Clinical Practice</i> , 2007 , 13, 265-71 | 2.5 | 7 |
| 1 | Antidepressants for patients with tinnitus. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD003853 | | 44 |